Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MGLL | Q99685 | 2/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 2/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | DRD2 | P14416 | 1/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.48 |
| ▸ | BCL9 | O00512 | 1/20 | 0.48 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31417142 | 0.94 | MAPT (0.53) | EPHX2ALDH1A1RAB9AMGLLEPHX1 | |
| SCHEMBL2383573 | 0.94 | ALDH1A1 (0.61) | ALDH1A1RAB9AEPHX1GAA | |
| SCHEMBL4070011 | 0.93 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL4182633 | 0.93 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL4175464 | 0.93 | ALDH1A1 (0.64) | ALDH1A1RAB9AEPHX1 | |
| SCHEMBL12436790 | 0.91 | MGLL (0.48) | EPHX2ALDH1A1RAB9AMGLLEPHX1 | |
| SCHEMBL25994 | 0.90 | MGLL (0.47) | EPHX2ALDH1A1RAB9AMGLLEPHX1 | |
| SCHEMBL29157993 | 0.89 | DRD2 (0.52) | EPHX2ALDH1A1RAB9AMGLLEPHX1 | |
| SCHEMBL11423759 | 0.88 | EPHX2 (0.55) | EPHX2ALDH1A1RAB9AMGLLEPHX1 | |
| SCHEMBL21227846 | 0.88 | HTR1A (0.48) | EPHX2ALDH1A1RAB9AMGLLGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12516056-B2 | Compounds for inhibition of janus kinase 1 | MANKIND PHARMA LTD. (IN) | 2026-01-06 | — | — | US | disclosed |
| EP-4463450-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | Bisichem Co., Ltd. (KR) | 2024-11-20 | — | — | EP | disclosed |
| CN-114174294-B | Novel compounds for inhibiting JANUS kinase 1 | 人类制药有限公司 | 2024-10-25 | — | — | CN | disclosed |
| CN-118510770-A | Fused heteroaryl hydroxamic acids as STING agonists | 比西切姆有限公司 | 2024-08-16 | — | — | CN | disclosed |
| WO-2023136589-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-20 | — | — | WO | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | BISICHEM CO., LTD. (KR) | 2023-07-13 | — | — | US | disclosed |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD. (IN) | 2022-07-28 | — | — | US | disclosed |
| EP-3976612-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | MANKIND PHARMA LTD (IN) | 2022-04-06 | — | — | EP | disclosed |
| EP-1966207-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | Pfizer Products Inc. (US) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007072158-A2 | PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF ABNORMAL CELL GROWTH | PFIZER PRODUCTS INC. (US) | 2007-06-28 | — | — | WO | disclosed |
| EP-1767533-A1 | N-{(2-(2,6-dioxo(3-piperidyl)-1,3-dioxo-2,3-dihydro-1H-isoindolin-4-yl)methyl}cyclopropylcarboxamide as TNF inhibitor | CELGENE CORPORATION (US) | 2007-03-28 | — | — | EP | disclosed |
| EP-1363900-B1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS AND USES THEREOF | CELGENE CORP (US) | 2007-01-24 | — | — | EP | disclosed |
| US-7091353-B2 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2006-02-02 | — | — | US | disclosed |
| EP-1363900-A1 | ISOINDOLE-IMIDE COMPOUNDS AS TNF-INHIBITORS | CELGENE CORPORATION (US) | 2003-11-26 | — | — | EP | disclosed |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-05-22 | — | — | US | disclosed |
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | CELGENE CORPORATION | 2003-03-06 | — | — | US | disclosed |
| WO-2002059106-A1 | ISOINDOLE-IMIDE COMPOUNDS, COMPOSITIONS, AND USES THEREOF | CELGENE CORPORATION (US) | 2002-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030045552-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | EPHX2 2239/4885ALDH1A1 2514/4885RAB9A 1120/4885 |
| US-20060025597-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, TNFRSF1A | EPHX2 2062/4885ALDH1A1 2190/4885RAB9A 996/4885 |
| US-20030096841-A1 | Isoindole-imide compounds, compositions, and uses thereof | TNF, IKZF3, IKZF1 | EPHX2 2239/4885ALDH1A1 2514/4885RAB9A 1120/4885 |
| US-20230219931-A1 | FUSED HETEROARYL HYDROXAMATES AS STING AGONISTS | STING1, IRF3, IFNAR1 | EPHX2 2221/4885ALDH1A1 4617/4885RAB9A 2704/4885 |
| US-20220235046-A1 | NOVEL COMPOUNDS FOR INHIBITION OF JANUS KINASE 1 | JAK1, JAK2, JAK3 | EPHX2 4009/4885ALDH1A1 2992/4885RAB9A 2722/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.